ASH 2020 - Multiple Myeloma
Preliminary results from a phase 2 study of isatuximab in patients with amyloid light-chain (AL) amyloidosis who were previously treated showed encouraging efficacy and a good safety profile.
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
Consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance proved superior to lenalidomide maintenance alone in progression-free survival and myeloma response among transplant-eligible patients with NDMM.
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
Although promising efficacy and acceptable toxicity were reported for belantamab mafodotin + pomalidomide + dexamethasone in patients with RRMM, the high rate of dose holds at the 2.5-mg/kg level warranted examination of alternative dosing schedules.
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Adding daratumumab to lenalidomide, bortezomib, and dexamethasone induction and consolidation, followed by maintenance with lenalidomide ± daratumumab for transplant-eligible patients with NDMM elicits deep and improving responses, with no additional safety concerns upon longer follow-up.
Results from a first-in-human study of AMG 701, an anti-BCMA BiTE molecule, showed an acceptable safety profile, promising efficacy, and a favorable pharmacokinetic profile in heavily pretreated patients with RRMM, thereby supporting ongoing evaluation.
Interim results from the STOMP study show that the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates and encouraging progression-free survival in heavily pretreated patients with multiple myeloma.
Circularly Permuted TRAIL, a Novel TRAIL Agonist, with Thalidomide and Dexamethasone in Patients with RRMM
Results from a phase 3 study of circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) + thalidomide and dexamethasone demonstrated this was a safe and effective treatment for patients with RRMM, including those with a poor prognosis.
Depth of Response of Isatuximab + Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Interim Analysis
The IKEMA study interim analysis showed isatuximab + carfilzomib and dexamethasone resulted in a clinically meaningful improvement in depth of response, with more patients reaching minimal residual disease–negativity compared with carfilzomib and dexamethasone alone.
The updated analysis of the phase 1 study of teclistamab in patients with RRMM shows favorable efficacy and manageable safety, and supports the planned phase 2 monotherapy trial at 1500 μg/kg administered subcutaneously.
Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, for RRMM
Results from a phase 1 study of talquetamab, a first-in-class bispecific antibody, show encouraging clinical activity with manageable toxicity in heavily pretreated patients with RRMM. The study is ongoing to identify a dose for phase 2 investigation.